Trial Profile

A Phase 1, Open-label, Single-dose, Multicenter, Parallel Group Study to Assess the Pharmacokinetics and Safety of Alpelisib (BYL719) in Subjects With Hepatic Impairment Compared to Matched Healthy Control Subjects.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpelisib (Primary)
Indications Breast cancer; Colorectal cancer; Gastrointestinal stromal tumours; Head and neck cancer; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Uveal melanoma
Focus Pharmacokinetics
Sponsors Novartis Pharmaceuticals Corporation

03 May 2018 Status changed from recruiting to completed.
16 Oct 2017 Planned End Date changed from 25 Sep 2017 to 15 Jan 2018.
16 Oct 2017 Planned primary completion date changed from 25 Sep 2017 to 15 Jan 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com